Kyle Kline
Chief Financial Officer at GMED
Executive
About Kyle Kline
Kyle Kline, age 40, was appointed Chief Financial Officer (principal financial and accounting officer) of Globus Medical on July 18, 2025, after serving as SVP of Finance since January 2024 and joining Globus in 2017 as Assistant Controller following nearly a decade at Deloitte & Touche LLP (Senior Manager, Audit). He holds a B.S. in accounting from Bloomsburg University and has “eight plus years” with Globus, spanning controllership, treasury, tax, and audit leadership . In his early tenure as CFO, Globus reported Q3 2025 net sales of $769.0M (+22.9% YoY), GAAP diluted EPS of $0.88 and non-GAAP diluted EPS of $1.18, with non-GAAP free cash flow of $213.9M; the company also increased FY25 guidance ranges (revenue to $2.86–$2.90B; non-GAAP EPS to $3.75–$3.85) .
Past Roles
| Organization | Role | Years | Strategic Impact |
|---|---|---|---|
| Globus Medical | SVP, Finance | Jan 2024–Jul 2025 | Led day-to-day accounting, finance, treasury, and tax; FP&A leadership |
| Globus Medical | Assistant Controller; roles of increasing responsibility | May 2017–Jan 2024 | Progressed through controllership and finance leadership roles |
External Roles
| Organization | Role | Years | Strategic Impact |
|---|---|---|---|
| Deloitte & Touche LLP | Senior Manager, Audit | ~10 years (pre-2017) | Led audits for large multinationals and PE portfolio companies in life sciences and manufacturing |
Fixed Compensation
| Year | Base Salary ($) | Target Bonus ($) | Notes |
|---|---|---|---|
| 2025 (appointed) | 345,000 | 200,000 | Initial CFO comp approved July 18, 2025 |
Performance Compensation
Annual Non-Equity Incentive Plan (Company framework)
| Metric | Weighting | Target | Actual | Payout Multiple | Payout Timing |
|---|---|---|---|---|---|
| Revenue | 90% (with Compliance & Quality reviewed for 10%) | $2,500,000,000 | $2,521,000,000 (100.8% of goal) | 111% of base reference amount | Paid following year (Feb 2025 for FY24) |
| Compliance & Quality | 10% (committee discretion) | Committee assessment | Committee assessment | Committee adjustment right | Incorporated into annual payout |
Equity Awards (Options-focused program)
| Feature | Terms |
|---|---|
| Equity form | Stock options expiring after 10 years; vest ratably over 4 years |
| 2021 Plan vesting floor | Awards generally cannot vest earlier than 1st anniversary; exceptions detailed in plan |
| Exercise price discipline | Not less than fair market value on grant date |
Kyle Kline Option Grants
| Grant/Instrument | Grant/Exercisable Dates | Expiration | Shares (#) | Exercise Price ($/sh) | Vesting |
|---|---|---|---|---|---|
| CFO appointment option grant | 07/18/2025 (grant) | — | 20,909 | — | 25% on 07/18/2026; remainder vest monthly over 36 months |
| Stock Option (Right to Buy Class A) | (1) Date exercisable per award | 01/25/2031 | 5,000 | 64.44 | As per prior award terms |
| Stock Option (Right to Buy Class A) | (2) Date exercisable per award | 08/09/2031 | 5,000 | 80.17 | As per prior award terms |
Equity Ownership & Alignment
| Item | Disclosure |
|---|---|
| Beneficial ownership (Kyle Kline) | Initial statement (Form 3) filed Aug 27, 2025; derivative (option) positions disclosed as above |
| Shares pledged as collateral | Company insider trading policy prohibits directors/officers (Section 16 filers) from pledging, hedging, or margin accounts |
| Ownership guidelines | Not disclosed in 2025 proxy for executive officers (no specific guideline text found for Kyle) — |
| Option plan design | Options at or above FMV, 10-year term, 4-year ratable vesting; 2021 Plan one-year minimum vesting with limited exceptions |
| In-the-money value (options) | Not provided in filings for Kyle; values depend on market price vs strike — |
Employment Terms
| Term | Details |
|---|---|
| Appointment | CFO effective July 18, 2025; principal financial and accounting officer |
| Age | 40 |
| Education | B.S., Accounting, Bloomsburg University |
| Compensation (cash) | Base $345,000; target bonus $200,000 (FY25 program) |
| Compensation (equity) | Option to buy 20,909 shares under 2021 Plan; 25% vests at first anniversary; remainder monthly over 36 months |
| Severance / CoC | No severance or change-in-control cash terms disclosed for Kyle in the 8-K; company-wide CoC option acceleration applies if awards not assumed |
| Clawback | Compensation Recoupment Policy effective Dec 1, 2023 per Dodd-Frank/NYSE; recovery of incentive comp upon restatement regardless of misconduct |
| Hedging/Pledging | Prohibited for directors and Section 16 officers (includes CFO) |
| Non-compete/Non-solicit | Not disclosed for Kyle in available filings — |
Track Record, Value Creation, and Execution Risk
- Q3 2025 results under CFO tenure: net sales $769.0M (+22.9% YoY), GAAP EPS $0.88, non-GAAP EPS $1.18, non-GAAP FCF $213.9M; management cited synergy capture and operational leverage from NuVasive and Nevro transactions .
- FY25 guidance raised to revenue $2.86–$2.90B and non-GAAP EPS $3.75–$3.85 (Nevro now accretive in 2025), highlighting confidence in integration and cost actions .
- Capital allocation under CFO: share repurchases of $40M in Q3 and $255.5M YTD through Q3 2025; authorization expanded by $500M in Q2, signaling confidence and discipline .
Vesting Schedules and Insider Selling Pressure
- 2025 CFO grant vests 25% at 12 months then monthly over 36 months; combined with prohibition on hedging/pledging, near-term selling pressure from Kyle’s awards is structurally limited until vesting occurs .
- Company equity program relies on time-vested options; RSUs/PSUs were not used for NEOs in 2024, which lowers explicit performance linkage but increases market-price sensitivity of realized pay .
Compensation Structure vs Performance Metrics
- Annual bonus design (FY24) tied primarily to revenue, with Compliance & Quality reviewed for 10%; FY24 revenue achieved 100.8% of target, resulting in 111% payout of base reference amounts (paid in Feb 2025) .
- Equity awards are time-vested stock options granted at or above FMV; no PSU metrics disclosed in 2024 for NEOs .
Related Policies and Governance
- Change-of-control: if awards under 2012/2021 Plan are not assumed/replaced, all awards vest/exercisable immediately prior to close (accelerated vesting protections) .
- Compensation Committee composition and independence disclosed; uses options and annual incentives to balance short-/long-term goals; committee retains discretion on payouts .
- Insider trading policy forbids hedging, pledging, and margin accounts for directors/Section 16 officers .
Insider Filings and Transactions
- Form 3 filed Aug 27, 2025, listing derivative option holdings for Kyle Kline (5,000 @ $64.44, expiring 01/25/2031; 5,000 @ $80.17, expiring 08/09/2031; plus additional awards not fully visible in retrieved excerpt) .
- Our document search surfaced certifications (Sarbanes-Oxley 302/906) and 8-K signatures under Kyle’s capacity as CFO; no Form 4 transactions for Kyle were returned in the searched corpus (not definitive) .
Investment Implications
- Alignment: Time-vested options and a strict anti-hedging/pledging policy indicate direct exposure to share price, aligning CFO incentives with shareholder outcomes; absence of disclosed RSUs/PSUs suggests realized equity value is market-driven rather than benchmarked to multi-factor scorecards .
- Retention: Four-year vesting on a 20,909-share grant at appointment supports retention; lack of disclosed severance for Kyle (vs. CEO/COO/GC who have severance terms) implies lower change-of-control cash obligations and potentially leaner executive parachutes .
- Execution signals: Guidance raises and sizable buybacks under CFO tenure point to confidence and ongoing synergy capture from NuVasive/Nevro, but continued integration and SG&A right-sizing (especially at Nevro) remain execution priorities that will drive margin trajectory and bonus outcomes .
- Trading watchpoints: With staged vesting and no pledging, near-term insider selling pressure from Kyle’s awards should be contained; monitor future Form 4 filings for exercises/sales around vest dates and any changes to equity mix in the next proxy cycle .